Abstract
A literature search on cerebral vasospasm yielded many research articles on the pathogenesis and management of cerebral vasospasm. A review was done touching on pathogenesis and pathophysiology, concentrating mainly on the prevention and treatment of vasospasm. A number of lines of treatment are under investigation. The main treatments to have reached the stage of clinical trial are endothelin antagonists, magnesium sulphate, and members of the statin group of drugs. Variations on calcium antagonists and cerebrospinal fluid drainage have also been reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andaluz N, Zuccarello M (2004) Fenestration of the lamina terminalis as a valuable adjunct in aneurysm surgery. Neurosurgery 55: 1050–1059
Belfort MA, Anthony J, Saade GR, Allen JC Jr, Nimodipine Study Group (2003) A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. New Eng J Med 348: 304–311
van den Bergh WM, Algra A, van Kooten F, Dirven CM, van Gijn J, Vermeulen M, Rinkel GJ (2005) Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 36: 1011–1015
van den Bergh WM, Dijkhuizen RM, Rinkel GJ (2004) Potentials of magnesium treatment in subarachnoid haemorrhage. Magnesium Res 17: 301–313
Chia RY, Hughes RS, Morgan MK (2002) Magnesium: a useful adjunct in the prevention of cerebral vasospasm following aneurysmal subarachnoid haemorrhage. J Clin Neurosci 9: 279–281
Dalbasti T, Karabiyikoglu M, Ozdamar N, Oktar N, Cagli S (2001) Efficacy of controlled-release papaverine pellets in preventing symptomatic cerebral vasospasm. J Neurosurg 95: 44–50
Dorsch NWC, King MT (1994) A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage. Part I: Incidence and effects. J Clin Neurosci 1: 19–26
Hansen-Schwartz J (2004) Cerebral vasospasm: a consideration of the various cellular mechanisms involved in the pathophysiology. Neurocrit Care 1: 235–246
Jeng AY, Mulder P, Kwan AL, Battistini B (2002) Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications [Review]. Can J Physiol Pharmacol 80: 440–449
Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T (2005) Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery 56: 895–902
Kessler IM, Pacheco YG, Lozzi SP, de Araujo AS Jr, Onishi FJ, de Mello PA (2005) Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol 64[Suppl 1]: 2–5
Klimo P Jr, Kestle JR, MacDonald JD, Schmidt RH (2004) Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg 100: 215–224
Lin CL, Jeng AY, Howng SL, Kwan AL (2004) Endothelin and subarachnoid hemorrhage-induced cerebral vasospasm: pathogenesis and treatment. Curr Med Chem 11: 1779–1791
Lynch JR, Wang H, McGirt MJ, Floyd J, Friedman AH, Coon AL, Blessing R, Alexander MJ, Graffagnino C, Warner DS, Laskowitz DT (2005) Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke 36: 2024–2026
Ono K, Matsumori A (2002) Endothelin antagonism with bosentan: current status and future perspectives [Review]. Cardiovasc Drug Rev 20: 1–18
Parra A, Kreiter KT, Williams S, Sciacca R, Mack WJ, Naidech AM, Commichau CS, Fitzsimmons BF, Janjua N, Mayer SA, Connolly ES Jr (2005) Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery 56: 476–484
Pluta RM (2005) Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther 105: 23–56
Prevedello DM, Corseiro JG, de Morais AL, Saucedo NS Jr, Chen IB, Araujo JC (2006) Magnesium sulfate: role as possible attenuating factor in vasospasm morbidity. Surg Neurol 65Suppl 1: 14–20
Suhardja A (2004) Mechanisms of disease: roles of nitric oxide and endothelin-1 in delayed cerebral vasospasm produced by aneurysmal subarachnoid hemorrhage. Nat Clin Pract Cardiovasc Med 1: 110–116
Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ (2005) Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 36: 1627–1632
Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P (2005) Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103: 9–17
Vatter H, Zimmermann M, Seifert V, Schilling L (2004) Experimental approaches to evaluate endothelin-A receptor antagonists. Meth Find Exp Clin Pharmacol 26: 277–286
Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, Marrocco A, Thomas AJ, Mitsias PD, Malik GM (2002) Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 96: 510–514
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag
About this paper
Cite this paper
Murray, M., Dorsch, N.W.C. (2008). Advances in vasospasm research. In: Kırış, T., Zhang, J.H. (eds) Cerebral Vasospasm. Acta Neurochirurgica Supplement, vol 104. Springer, Vienna. https://doi.org/10.1007/978-3-211-75718-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-211-75718-5_1
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-75717-8
Online ISBN: 978-3-211-75718-5
eBook Packages: MedicineMedicine (R0)